Former UK Prime Minister David Cameron is advocating for the creation of a specialized dementia drug fund to expedite patient access to new Alzheimer's treatments. This proposal arrives as the National Health Service (NHS) remains locked in a pricing dispute over two recently licensed medications.
The £80,000 price tag stalling NHS access to donanemab and lecanemab
The current impasse centers on two pioneering drugs, donanemab (produced by Eli Lilly) and lecanemab (produced by Eisai), both of which received UK licensing in 2024. According to the report, negotiations between the NHS and the manufacturers began in July and were expected to conclude within 49 days, but they have since dragged on for months due to disagreements over cost and access.
The financial friction is significant, as private market prices for these therapies are reportedly hovering around £80,000 per year. Because of this stalemate, the National Institute for Health and Care Excellence (NICE) has paused its appraisal process while NHS England continues to seek a sustainable financial agreement with the drug makers.
Applying the 16-year-old model of the cancer drugs fund to dementia
David Cameron, who now serves as the president of Alzheimer's Research UK, argues that the government should emulate the cancer drugs fund he introduced 16 years ago. that initiative was specifically designed to remove bureaucratic and financial roadblocks, allowing patients to access expensive new oncology therapies more rapidly. As reported, Cameron believes a similar targeted funding stream could overcome current affordability barriers for dementia care .
This push is deeply personal for the former Prime Minister, whose mother, Mary Cameron, passed away from Alzheimer's last year at age 90. Cameron asserts that while the medical community has finally developed therapies that address the underlying pathology of the disease, the current UK health system is failing to deliver those breakthroughs to the people who need them.
A 30 percent slowdown in disease progression for early-stage patients
The urgency of the proposal is underscored by clinical data showing that donanemab and lecanemab can slow the progression of Alzheimer's by approximately 30 perent. this clinical benefit translates to an estimated six additional months of stability before a patient experiences further deterioration. For those in the earliest stages of the disease,this window of time is critical for maintaining quality of life.
The Alzheimer's Society has highlighted the human cost of the current delay. Chief executive Michelle Dyson has described patients as "desperate" for the approval of these treatments, noting that the window for eligibility is narrow since the drugs only benefit those in the initial phases of the condition.
Who will fund the gap for hundreds of thousadns of eligible English patients?
A primary unresolved issue is how the UK will manage the sheer scale of demand, as several hundred thousand people in England could potentially qualify for treatment if the drugs are approved for NHS use. While the report mentions that NHS spokespersons are working to balance patient access with financial sustainability, it remains unclear exactly where the funding for a new dedicated fund would originate—whether from new government appropriations or a reallocation of existing health budgets.
Furthermore, the source does not provide a response from Eli Lilly or Eisai regarding whether they are willing to lower their pricing to avoid the need for a separate fund. This leaves a critical question: is the proposed fund a genuine solution for patient access, or a mechanism to allow the NHS to pay premium prices that the current budget cannot sustain?
Comments 0